Clinical Trial Update: Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Aza-Ven followed by reduced toxicity conditioning regimen (MBF) as salvage therapy for refractory acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Aza-Ven (azacitidine-venetuzumab? (unclear from title; provide best guess if known))

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Refractory Acute Myeloid Leukemia | Phase 2 | Status: UNKNOWN